These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 7687807

  • 1. Insulin-like growth factors (IGF) I and II and IGF binding proteins 1, 2 and 3 during low-dose growth hormone (GH) infusion and sequential euglycemic and hypoglycemic glucose clamps: studies in GH-deficient patients.
    Jørgensen JO, Blum WF, Horn N, Møller N, Møller J, Ranke MB, Christiansen JS.
    Acta Endocrinol (Copenh); 1993 Jun; 128(6):513-20. PubMed ID: 7687807
    [Abstract] [Full Text] [Related]

  • 2. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
    Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Blum WF, Drop SL.
    J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
    [Abstract] [Full Text] [Related]

  • 3. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T, Jørgensen JO, Jakobsen G, Hansen BL, Christiansen JS.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [Abstract] [Full Text] [Related]

  • 4. Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients.
    Laursen T, Jørgensen JO, Orskov H, Møller J, Harris AG, Christiansen JS.
    Acta Endocrinol (Copenh); 1993 Nov; 129(5):399-408. PubMed ID: 7506470
    [Abstract] [Full Text] [Related]

  • 5. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients.
    Laursen T, Møller J, Jørgensen JO, Orskov H, Christiansen JS.
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):333-9. PubMed ID: 8949572
    [Abstract] [Full Text] [Related]

  • 6. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
    Laursen T, Jørgensen JO, Christiansen JS.
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
    [Abstract] [Full Text] [Related]

  • 7. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.
    Hilding A, Brismar K, Degerblad M, Thorén M, Hall K.
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2646-52. PubMed ID: 7545695
    [Abstract] [Full Text] [Related]

  • 8. Pregnancy in growth hormone-deficient rats: assessment of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs) and IGFBP protease activity.
    Gargosky SE, Nanto-Salonen K, Tapanainen P, Rosenfeld RG.
    J Endocrinol; 1993 Mar; 136(3):479-89. PubMed ID: 7682593
    [Abstract] [Full Text] [Related]

  • 9. Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients.
    Jørgensen JO, Blum WF, Møller N, Ranke MB, Christiansen JS.
    J Clin Endocrinol Metab; 1991 Mar; 72(3):582-7. PubMed ID: 1705258
    [Abstract] [Full Text] [Related]

  • 10. Circadian patterns of serum insulin-like growth factor (IGF) II and IGF binding protein 3 in growth hormone-deficient patients and age- and sex-matched normal subjects.
    Jørgensen JO, Blum WF, Møller N, Ranke MB, Christiansen JS.
    Acta Endocrinol (Copenh); 1990 Sep; 123(3):257-62. PubMed ID: 1700568
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children.
    Smith WJ, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR.
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1294-9. PubMed ID: 7521346
    [Abstract] [Full Text] [Related]

  • 16. Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats.
    Gargosky SE, Tapanainen P, Rosenfeld RG.
    Endocrinology; 1994 May; 134(5):2267-76. PubMed ID: 7512499
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1.
    Cotterill AM, Daly F, Holly JM, Hughes SC, Camacho-Hübner C, Abdulla AF, Gale EA, Savage MO.
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):567-74. PubMed ID: 8548941
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone on serum IGF-binding proteins in calorically restricted adults.
    Young SC, Underwood LE, Celniker A, Clemmons DR.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):603-8. PubMed ID: 1379258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.